Led by partner Jason Breen, who has guided Repligen Corporation (NASDAQ:RGEN) through several strategic M&A transactions since 2014, the Life Sciences team represented Repligen on its definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock. Repligen expects the acquisition of C Technologies will establish the company in the rapidly growing Process Analytics segment of bioprocessing with best-in-class protein measurement technologies and a strong foundation for next-generation product development.
The transaction is expected to close during the second quarter of 2019, subject to the satisfaction of customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Repligen is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Its portfolio includes protein products (Protein A affinity ligands including NGL Impact™-A, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems).
For additional details on the acquisition, please read the press release.